Goserelin (Zoladex) - Complete Research Paper

1. Summary

Goserelin is a synthetic gonadotropin-releasing hormone (GnRH) agonist administered as a subcutaneous implant for the treatment of hormone-sensitive malignancies and benign gynecological conditions. Marketed under the brand name Zoladex by AstraZeneca, goserelin was first patented in 1976 and received FDA approval in 1989, establishing itself as a foundational agent in hormonal manipulation therapy.

Goserelin holds the unique distinction of being the only GnRH agonist with FDA approval for treating hormone receptor-positive breast cancer in pre- and perimenopausal women, making it irreplaceable in this specific clinical niche. The drug functions through initial stimulation followed by sustained suppression of the hypothalamic-pituitary-gonadal axis, ultimately achieving medical castration levels of sex hormones within 2-4 weeks of initiation.

Available in two depot formulations (3.6 mg monthly and 10.8 mg every 3 months), goserelin offers convenient dosing schedules that enhance patient compliance compared to daily or more frequent administration regimens. The subcutaneous implant delivery system provides sustained-release pharmacokinetics, maintaining therapeutic hormone suppression throughout the dosing interval.

FDA-approved indications include advanced prostate cancer, hormone receptor-positive breast cancer in premenopausal women, endometriosis, and endometrial thinning prior to ablation procedures. The 2024 NCCN guidelines continue to recommend goserelin as a preferred option for ovarian function suppression in breast cancer treatment protocols.

Common adverse effects reflect the drug's mechanism of inducing hypogonadism, including hot flashes, decreased libido, bone mineral density loss, and injection site reactions. Unlike some alternatives, goserelin implants do not require refrigeration, offering practical advantages in clinical settings.

2. Mechanism of Action

Goserelin is a synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH, also called luteinizing hormone-releasing hormone or LHRH). The molecule contains a modification at the sixth amino acid position (substitution of glycine with D-serine) and a C-terminal azaglycinamide modification, rendering it resistant to enzymatic degradation and providing extended biological activity.

Initial Agonist Phase (Flare Phenomenon): Upon administration, goserelin binds to GnRH receptors in the anterior pituitary gland, initially stimulating the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This stimulation causes a transient surge in gonadal hormone production:

• In males: Testosterone levels may increase 50-100% above baseline during the first 1-2 weeks
• In females: Estradiol levels transiently rise before suppression occurs

This "flare" phenomenon is clinically significant in prostate cancer patients, where testosterone surge can temporarily exacerbate disease symptoms including bone pain and urinary obstruction. Antiandrogen co-administration is typically employed during the first weeks of therapy to mitigate flare effects.

Sustained Suppression Phase: Continuous GnRH receptor stimulation leads to receptor downregulation and desensitization within the pituitary gonadotroph cells. By weeks 2-4, this results in:

• Profound suppression of LH and FSH secretion
• Reduction of serum testosterone to castrate levels (<50 ng/dL or <1.7 nmol/L) in males
• Reduction of serum estradiol to postmenopausal levels (<20 pg/mL) in females
• Cessation of ovarian function and amenorrhea in premenopausal women

Downstream Effects:

• Prostate cancer: Androgen deprivation arrests testosterone-dependent tumor growth
• Breast cancer: Estrogen suppression removes growth stimulus for ER-positive tumors
• Endometriosis: Hypoestrogenic state induces atrophy of ectopic endometrial tissue
• Endometrial thinning: Reduced estrogen leads to endometrial atrophy facilitating ablation

The effects of goserelin are reversible upon discontinuation, with return of normal gonadal function typically occurring within 8-12 weeks, though prolonged use may delay recovery.

3. FDA-Approved Indications

Prostate Cancer (FDA Approved 1989):

• Palliative treatment of advanced carcinoma of the prostate (Stage D2)
• Both 3.6 mg (monthly) and 10.8 mg (3-month) formulations approved
• First-line hormonal therapy or in combination with antiandrogen (combined androgen blockade)
• Neoadjuvant/adjuvant use with radiation therapy for locally advanced disease

Breast Cancer (FDA Approved - Unique Indication):

• Palliative treatment of advanced breast cancer in pre- and perimenopausal women
• Only GnRH agonist with this specific FDA approval (distinguishes from leuprolide, triptorelin)
• Ovarian function suppression (OFS) as component of adjuvant therapy for hormone receptor-positive disease
• 2024 NCCN Guidelines recommend goserelin for OFS in combination with tamoxifen or aromatase inhibitors

Endometriosis (FDA Approved):

• Management of endometriosis, including pain relief and reduction of endometriotic lesions
• Approved for treatment duration up to 6 months
• May be used preoperatively to reduce lesion size before surgical intervention

Endometrial Thinning (FDA Approved):

• Adjunct therapy for endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding
• Single 3.6 mg dose administered 4 weeks before ablation procedure
• Facilitates surgical outcomes by reducing endometrial thickness

Off-Label Uses (Not FDA-Approved):

• Central precocious puberty (leuprolide preferred due to established dosing)
• Gender-affirming hormone therapy (puberty suppression)
• Uterine leiomyomata (fibroids) - size reduction before surgery
• In vitro fertilization protocols (pituitary downregulation)
• Polycystic ovarian syndrome management

4. Dosing and Administration

Available Formulations:

• Zoladex 3.6 mg: Cylindrical depot implant (diameter ~1 mm, length ~15 mm) in pre-filled syringe
• Zoladex 10.8 mg: Larger depot implant (diameter ~1.5 mm, length ~20 mm) in pre-filled syringe

Administration Technique:

• Route: Subcutaneous injection into anterior abdominal wall below the navel line
• Needle: 14-16 gauge pre-attached to syringe (larger than typical injections)
• Patient positioning: Supine with area cleaned; local anesthetic optional but rarely needed
• Technique: Insert needle at 30-45° angle, advance until hub reaches skin, depress plunger fully
• Implant biodegrades completely over dosing interval; no removal necessary

Indication-Specific Dosing:

Prostate Cancer:

• 3.6 mg subcutaneously every 28 days, OR
• 10.8 mg subcutaneously every 12 weeks (84 days)
• Continue indefinitely or until disease progression
• Consider antiandrogen flare protection for first 2-4 weeks

Breast Cancer:

• 3.6 mg subcutaneously every 28 days
• Duration per oncology protocol: commonly 2-5 years for adjuvant therapy
• 10.8 mg formulation is FDA-approved but 3.6 mg monthly is standard practice

Endometriosis:

• 3.6 mg subcutaneously every 28 days
• Maximum recommended duration: 6 months (due to bone density concerns)
• Add-back therapy (low-dose estrogen/progestin) may be considered to reduce hypoestrogenic symptoms

Endometrial Thinning:

• Single 3.6 mg implant administered 4 weeks (28 days) before planned ablation procedure
• One-time use; no repeat dosing required

Timing Considerations:

• First injection ideally during Days 1-5 of menstrual cycle (if applicable) to avoid inadvertent use during pregnancy
• Subsequent doses should be administered on or before the scheduled date to maintain suppression
• If dose delayed >3 days beyond scheduled date, breakthrough ovulation/testosterone recovery may occur

Age-Stratified Dosing Guidelines

Age significantly influences both the indications for goserelin use and the monitoring intensity required. These guidelines provide age-specific considerations for optimal therapy.

Pediatric/Adolescent (Off-Label Use)

Clinical Context:

• Not FDA-approved for pediatric use
• Off-label use in central precocious puberty (leuprolide preferred)
• Off-label use for gender-affirming puberty suppression

Dosing Considerations:

• 3.6 mg monthly is typical if goserelin selected
• Weight-based dosing not established; fixed-dose implant used
• Close monitoring of growth parameters and bone age required

Key Concerns:

• Long-term bone density effects in developing skeleton
• Psychological support essential during puberty suppression
• Reversible upon discontinuation; puberty resumes

Adults 18-35 Years

Typical Indications:

• Endometriosis (most common)
• Fertility preservation during chemotherapy
• Early breast cancer (premenopausal)
• Gender-affirming hormone therapy (MTF)

Dosing Recommendations:

Key Considerations:

• Fertility preservation is paramount concern
• Bone density loss more significant given longer remaining lifespan
• Add-back therapy recommended for endometriosis to protect bone
• Discuss fertility banking before cancer treatment

Adults 35-50 Years

Typical Indications:

• Breast cancer (premenopausal/perimenopausal)
• Endometriosis
• Uterine fibroids (off-label)
• Early prostate cancer (less common at this age)

Dosing Recommendations:

Key Considerations:

• Perimenopausal status affects baseline hormone levels
• May have accelerated menopausal symptoms
• Bone density baseline assessment recommended
• Cardiovascular risk assessment before long-term therapy

Adults 50-65 Years

Typical Indications:

• Prostate cancer (most common goserelin indication)
• Breast cancer (if still premenopausal)

Dosing Recommendations:

Key Considerations:

• Cardiovascular risk assessment mandatory (FDA warning)
• Baseline bone density evaluation recommended
• Higher baseline osteoporosis risk
• Monitor metabolic parameters (glucose, lipids)
• Consider bone-protective therapy (bisphosphonates, denosumab)

Adults 65+ Years

Typical Indications:

• Advanced prostate cancer (primary indication)

Dosing Recommendations:

• Standard dosing applies (3.6 mg monthly or 10.8 mg quarterly)
• No pharmacokinetic dose adjustment required
• Clinical monitoring should be intensified

Key Considerations:

• Highest cardiovascular event risk population
• Pre-existing osteoporosis common; DEXA recommended
• Cognitive effects may be more pronounced
• Fall risk assessment important
• Drug interactions more likely (polypharmacy)
• Quality of life considerations paramount
• Discuss goals of care and ADT duration

Age-Stratified Dosing Summary Table

Sex-Specific Considerations

Males (Prostate Cancer):

• Primary indication for goserelin in males
• Antiandrogen cover for first 2-4 weeks essential
• Monitor for tumor flare symptoms (bone pain, urinary obstruction)
• Long-term therapy: address gynecomastia, sexual dysfunction, bone loss
• Consider intermittent ADT in select cases

Females (Breast Cancer, Endometriosis):

• Unique FDA indication for breast cancer OFS
• Premenopausal/perimenopausal status affects response
• Menopausal symptoms may be more severe
• Fertility preservation counseling mandatory before cancer treatment
• Add-back therapy for endometriosis to reduce side effects

5. Pharmacokinetics

Absorption:

• Route: Subcutaneous implant designed for slow, sustained release
• Bioavailability: Approximately 90% from subcutaneous depot
• Time to peak concentration: 12-15 days after 3.6 mg implant; slightly longer for 10.8 mg
• Peak serum concentration: 2.5-3.5 ng/mL (variable based on formulation and individual)

Distribution:

• Volume of distribution: 44.1 L (indicating moderate tissue distribution)
• Protein binding: 27% (primarily to albumin)
• Distribution half-life: 4.2 hours
• Does not significantly cross blood-brain barrier

Metabolism:

• Primary route: Hydrolysis by tissue and serum peptidases
• Metabolites: Amino acid fragments (pharmacologically inactive)
• No hepatic cytochrome P450 involvement
• No active metabolites identified

Elimination:

• Elimination half-life: 4.2 hours (terminal phase after depot release)
• Clearance: 121 mL/min (primarily renal for metabolites)
• Excretion: >90% renal elimination of metabolite fragments
• Fecal excretion: <10%
• Implant biodegradation: Complete within dosing interval (28 or 84 days)

Duration of Effect:

• 3.6 mg implant: Maintains castrate hormone levels for 28 days
• 10.8 mg implant: Maintains castrate hormone levels for 84 days (12 weeks)
• Testosterone suppression achieved: Typically by day 14-21
• Estradiol suppression achieved: Typically by day 21-28
• Recovery after discontinuation: 8-12 weeks for return of gonadal function

Special Population Pharmacokinetics:

• Renal impairment: No dose adjustment required despite renal elimination (metabolites inactive)
• Hepatic impairment: No dose adjustment required (minimal hepatic metabolism)
• Age: No clinically significant differences in pharmacokinetics
• Gender: Comparable absorption and elimination between males and females
• Body weight: May affect implant absorption rate but not overall exposure

6. Side Effects and Adverse Reactions

Very Common (>10% incidence):

Hormonal Suppression Effects:

• Hot flashes/flushes: 62-75% (most common adverse event in both sexes)
• Decreased libido: 45-60%
• Sexual dysfunction: 40-55% (erectile dysfunction in males, vaginal dryness in females)
• Night sweats: 30-45%
• Mood changes/emotional lability: 25-35%

Metabolic Effects:

• Weight changes (gain or loss): 10-15%
• Fatigue/lethargy: 15-25%

Local Reactions:

• Injection site pain/discomfort: 15-25% (related to larger gauge needle)
• Injection site induration: 10-15%
• Bruising at injection site: 8-12%

Common (1-10% incidence):

Cardiovascular:

• Peripheral edema: 5-8%
• Hypertension: 4-7%
• Palpitations: 2-4%

Musculoskeletal:

• Bone pain: 5-15% (may indicate tumor flare in prostate cancer)
• Joint pain/arthralgia: 4-8%
• Muscle weakness: 3-6%

Neurological:

• Headache: 5-10%
• Dizziness: 3-6%
• Paresthesias: 2-4%

Dermatological:

• Sweating (beyond hot flashes): 6-10%
• Acne: 3-5%
• Skin rash: 2-4%

Gastrointestinal:

• Nausea: 4-8%
• Constipation: 3-5%
• Diarrhea: 2-4%

Serious Adverse Reactions:

Tumor Flare (Prostate Cancer):

• Initial testosterone surge can worsen symptoms in first 2 weeks
• Bone pain exacerbation, spinal cord compression possible
• Urinary obstruction, urinary retention
• Prevention: Concurrent antiandrogen therapy for first 2-4 weeks

Bone Mineral Density Loss:

• Mean decrease 3-4% per year of treatment at lumbar spine
• Increased fracture risk with prolonged therapy (>6 months)
• Partially reversible upon discontinuation
• Consider baseline DEXA scan and calcium/vitamin D supplementation

Cardiovascular Events:

• FDA warning (2010): Increased risk of diabetes, heart attack, stroke, sudden cardiac death
• Class effect for all GnRH agonists
• Risk increases with duration of therapy and pre-existing CV disease
• Shared decision-making recommended regarding ADT duration

Allergic/Hypersensitivity:

• Rare anaphylactic reactions reported (<0.1%)
• Angioedema possible
• Cross-reactivity with other GnRH analogs may occur

7. Drug Interactions

Clinically Significant Interactions:

QT-Prolonging Medications:

• Goserelin may prolong QT interval (androgen deprivation effect)
• Use caution with other QT-prolonging agents:
  • Class IA/III antiarrhythmics (quinidine, amiodarone, sotalol)
  • Antipsychotics (haloperidol, ziprasidone)
  • Fluoroquinolones (moxifloxacin)
  • Macrolide antibiotics (erythromycin, azithromycin)
• Consider baseline and periodic ECG monitoring when combining

Hypoglycemic Agents:

• GnRH agonist therapy associated with insulin resistance and diabetes
• May reduce effectiveness of antidiabetic medications
• Monitor blood glucose more frequently during goserelin therapy
• Dose adjustments of metformin, sulfonylureas, or insulin may be needed

Moderate Interactions:

Anticoagulants:

• Theoretical interaction with warfarin (case reports of altered INR)
• Mechanism unclear; may relate to changes in hepatic function
• Monitor INR closely during initiation of goserelin in warfarin patients

Hormone Preparations:

• Exogenous estrogens or testosterone would counteract goserelin's therapeutic effects
• Discontinue HRT or testosterone therapy before initiating goserelin
• Exception: Add-back therapy in endometriosis (low-dose, intentional)

Bone-Active Medications:

• Bisphosphonates may be beneficial to counteract bone loss
• No pharmacokinetic interaction; pharmacodynamic benefit
• Denosumab provides alternative bone protection

Drugs with No Significant Interactions:

No CYP450 Interactions:

• Goserelin is metabolized by peptidases, not hepatic enzymes
• No interactions with CYP3A4, CYP2D6, or other CYP substrates
• Statins, SSRIs, NSAIDs, proton pump inhibitors: no dose adjustment needed

Chemotherapy:

• No pharmacokinetic interactions with standard chemotherapy regimens
• Can be safely combined with docetaxel, abiraterone, enzalutamide in prostate cancer
• Can be combined with tamoxifen or aromatase inhibitors in breast cancer

Laboratory Test Interference:

• Suppresses testosterone/estradiol levels (therapeutic effect, not interference)
• May affect FSH and LH assay interpretation (suppressed values expected)
• Prostate-specific antigen (PSA) levels should decline with effective therapy
• No interference with standard chemistry panels or hematology

8. Contraindications

Absolute Contraindications:

Hypersensitivity:

• Known hypersensitivity to goserelin, GnRH, GnRH analogs, or any excipient
• History of anaphylaxis to previous goserelin administration
• Cross-sensitivity possible with leuprolide, triptorelin, and other LHRH agonists

Pregnancy:

• Pregnancy Category X (contraindicated)
• May cause fetal harm; teratogenic potential in animal studies
• Pregnancy must be excluded before initiating therapy in women of reproductive potential
• Use effective non-hormonal contraception during therapy

Breastfeeding:

• Contraindicated during lactation
• Unknown whether goserelin or metabolites are excreted in breast milk
• Potential for serious adverse reactions in nursing infants

Relative Contraindications/Precautions:

Vertebral Metastases (Prostate Cancer):

• Risk of spinal cord compression during initial tumor flare
• Not an absolute contraindication but requires close monitoring
• Initiate concurrent antiandrogen and consider short hospitalization
• Neurosurgical backup recommended

Urinary Obstruction (Prostate Cancer):

• Risk of acute obstruction worsening during flare
• Consider urological intervention (catheter) before or during initiation
• Antiandrogen cover essential

Undiagnosed Vaginal Bleeding:

• Must rule out malignancy or other pathology before treating with goserelin
• Hypoestrogenic state may mask underlying pathology

Osteoporosis or High Fracture Risk:

• Use with caution; goserelin accelerates bone loss
• Baseline DEXA recommended
• Consider bone-protective therapy if long-term use anticipated

Cardiovascular Disease:

• Increased CV risk associated with androgen deprivation therapy
• FDA warning applies to all GnRH agonists
• Risk-benefit discussion essential in patients with pre-existing heart disease

Depression or Mood Disorders:

• Hormonal suppression may exacerbate mood symptoms
• Monitor closely for worsening depression or suicidal ideation
• Psychiatric evaluation recommended in patients with significant history

9. Special Populations

Pediatric Patients:

• Not FDA-approved for use in children
• Off-label use in central precocious puberty (leuprolide has established pediatric indication)
• Off-label use for gender-affirming puberty suppression
• Safety and efficacy data limited in pediatric population
• Same mechanism and expected outcomes as in adults

Geriatric Patients:

• No specific dose adjustment required for elderly
• Majority of prostate cancer patients are >65 years; extensive experience
• Increased baseline cardiovascular risk requires careful monitoring
• Higher baseline osteoporosis risk; bone protection often warranted
• Cognitive effects may be more pronounced in elderly (androgen deprivation)

Renal Impairment:

• No dose adjustment required
• Metabolites are renally eliminated but pharmacologically inactive
• Safe in all stages of chronic kidney disease
• Dialysis patients: No additional considerations needed

Hepatic Impairment:

• No dose adjustment required
• Minimal hepatic metabolism (peptidase-mediated, not CYP450)
• Safe in patients with hepatic dysfunction
• No specific monitoring requirements beyond standard care

Pregnancy:

• Category X: Contraindicated
• Exclude pregnancy before administration
• Advise effective contraception during therapy
• If pregnancy occurs during treatment, discontinue immediately
• Report exposure to manufacturer for registry tracking

Lactation:

• Contraindicated during breastfeeding
• Recommend discontinuing nursing before initiating therapy
• No data on milk excretion in humans

Obese Patients:

• Standard dosing applies regardless of body weight
• Implant depot system provides consistent release
• Subcutaneous fat may theoretically affect absorption but no clinical significance demonstrated
• Ensure adequate needle insertion depth in patients with thick subcutaneous tissue

Transgender Medicine:

• Used off-label for puberty suppression in transgender youth
• Provides reversible hormone suppression before gender-affirming hormones
• Typically continued until cross-sex hormone initiation
• Same 3.6 mg monthly dosing used
• Effects fully reversible upon discontinuation

10. Monitoring Parameters

Baseline Assessment (Before Treatment):

All Patients:

• Complete medical history including cardiovascular and bone health
• Physical examination
• Pregnancy test (women of reproductive potential) - REQUIRED before first dose
• ECG (baseline QT interval assessment recommended)
• Fasting glucose and HbA1c (diabetes risk)
• Lipid panel (metabolic effects)

Prostate Cancer:

• Serum testosterone level (baseline for comparison)
• PSA level (baseline and for monitoring response)
• DEXA scan if treatment anticipated >6 months

Breast Cancer:

• Serum estradiol level (baseline)
• DEXA scan (bone health baseline)
• Consider ovarian function markers (FSH, LH) in perimenopausal patients

Endometriosis/Gynecological:

• Serum estradiol level
• DEXA scan if treatment >6 months planned
• Document menstrual history

Ongoing Monitoring:

Hormone Levels:

• Testosterone (prostate cancer): Check at 1 month to confirm castrate levels (<50 ng/dL)
• Recheck testosterone every 3-6 months or if clinical progression suspected
• Estradiol (breast cancer/gynecological): Check at 1 month, then periodically

Tumor Markers:

• PSA (prostate cancer): Check at 3 months, then every 3-6 months
• Rising PSA on therapy indicates castrate-resistant disease

Bone Health:

• DEXA scan annually during prolonged therapy
• Consider more frequent monitoring if baseline osteopenia
• Calcium and vitamin D levels if supplementing

Metabolic Parameters:

• Fasting glucose: Every 3-6 months initially, then annually
• HbA1c: Every 6-12 months
• Lipid panel: Annually
• Weight: Each visit

Cardiovascular:

• Blood pressure: Each visit
• ECG: Periodically if on QT-prolonging medications or symptoms develop

Clinical Assessment:

• Hot flash severity and quality of life: Each visit
• Mood assessment: Each visit (screen for depression)
• Sexual function: As clinically indicated
• Injection site: Inspect at each administration

11. Cost and Availability

Brand Name Products:

• Zoladex 3.6 mg (AstraZeneca): ~$550-650 per implant (AWP)
• Zoladex 10.8 mg (AstraZeneca): ~$1,400-1,600 per implant (AWP)
• Zoladex LA (10.8 mg, some markets): Same as 10.8 mg formulation

Generic Availability:

• No FDA-approved generic goserelin implants available in the United States (as of 2024)
• Patent protections on delivery system have limited generic entry
• Some international markets have biosimilar/generic versions
• Complex depot delivery system creates manufacturing barriers

Annual Treatment Costs (Approximate):

• 3.6 mg monthly: $6,600-7,800 per year (13 implants)
• 10.8 mg quarterly: $5,600-6,400 per year (4 implants)
• The 3-month formulation offers modest cost savings (~15-20%)

Insurance Coverage:

• Generally covered under medical benefit (physician-administered)
• Medicare Part B covers when administered in physician office
• Prior authorization commonly required
• Step therapy through oral antiandrogens may be required before approval
• Specialty pharmacy distribution typical

Comparison with Competitors: | Product | Monthly Cost | Annual Cost | |------

Goal Relevance:

• Managing hormone-sensitive breast cancer in premenopausal women to improve treatment outcomes and reduce tumor growth.
• Alleviating symptoms and reducing lesions associated with endometriosis to improve quality of life and ease pain.
• Supporting prostate cancer treatment by reducing testosterone levels to slow cancer progression.
• Preparing for endometrial ablation by thinning the endometrium to enhance surgical success and reduce bleeding.
• Seeking alternatives for managing symptoms of advanced prostate cancer when other treatments are not suitable.
• Addressing hormone-related symptoms such as hot flashes and decreased libido due to medical treatment of cancer.
• Using hormone suppression as part of a comprehensive approach to managing hormone receptor-positive breast cancer.

Goal Archetype Integration

Goserelin (Zoladex) is a GnRH agonist subcutaneous implant that achieves medical castration through sustained hormone suppression. Understanding how goserelin integrates with specific clinical goals helps clinicians select the appropriate patient populations and optimize treatment protocols.

Cancer Treatment Goals

Prostate Cancer:

Breast Cancer (Unique FDA Indication):

Gynecological Goals

Endometriosis Management:

• Primary Goal: Pain relief and lesion reduction through hypoestrogenic state
• Mechanism: Atrophy of ectopic endometrial tissue via estrogen deprivation
• Protocol: 6-month maximum duration; add-back therapy (low-dose E/P) to mitigate bone loss and vasomotor symptoms
• Expected Outcome: 80-90% pain relief; significant lesion size reduction

Endometrial Thinning (Pre-Ablation):

• Primary Goal: Optimize surgical outcomes for endometrial ablation
• Mechanism: Reduced estrogen leads to endometrial atrophy (<5mm thickness)
• Protocol: Single 3.6 mg implant 4 weeks before procedure
• Expected Outcome: Improved ablation success rates, reduced intraoperative bleeding

When Goserelin is the Optimal Choice

Choose Goserelin When:

1. Breast cancer in premenopausal women (only FDA-approved GnRH agonist)
2. Room temperature storage required (clinic logistics, patient storage)
3. Monthly or quarterly subcutaneous depot preferred over daily/IM options
4. Patient has established good tolerance to goserelin
5. Long-term therapy planned (convenient 3-month option)

Consider Alternatives When:

• Rapid castration required urgently (GnRH antagonist achieves faster suppression)
• Flare risk is unacceptable (spinal cord compression, urinary obstruction)
• Patient prefers oral therapy (relugolix)
• Central precocious puberty indication (leuprolide has FDA approval)
• Cost is primary concern (generic leuprolide available)

Goal-Based Formulation Selection

---|--------------|-------------| | Goserelin 3.6 mg | ~$600 | ~$7,200 | | Goserelin 10.8 mg | ~$500/month | ~$6,000 | | Leuprolide depot 7.5 mg | ~$650 | ~$7,800 | | Eligard (leuprolide) 22.5 mg | ~$500/month | ~$6,000 | | Triptorelin 3.75 mg | ~$700 | ~$8,400 | | Degarelix 240/80 mg | ~$800 | ~$9,600 |

Patient Assistance Programs:

• AstraZeneca Patient Assistance Program (AZ&Me): Free medication for qualifying uninsured patients
• Income requirements typically <300-400% federal poverty level
• Foundation programs available for copay assistance
• Cancer care organizations may provide financial support

Distribution:

• Available through specialty distributors
• Most administered in oncology, urology, or gynecology offices
• No refrigeration required (significant advantage)
• Shelf-stable at room temperature (15-25°C/59-77°F)

12. Clinical Evidence Summary

Prostate Cancer Evidence:

SWOG 8894 Study (1995):

• Compared goserelin + flutamide vs. orchiectomy + flutamide
• N = 1,387 patients with advanced prostate cancer
• No significant difference in overall survival between medical and surgical castration
• Established goserelin as equivalent alternative to surgical castration

EORTC 22863 (Bolla et al., 2002):

• Goserelin 3 years + radiotherapy vs. radiotherapy alone
• N = 415 locally advanced prostate cancer patients
• 5-year overall survival: 78% vs. 62% (p=0.0002)
• Established long-term adjuvant ADT as standard of care

TROG 96.01 (2011):

• Compared 3 months vs. 6 months goserelin + radiotherapy
• Both durations with radiotherapy superior to radiotherapy alone
• 10-year prostate cancer mortality significantly reduced

Breast Cancer Evidence:

SOFT Trial (2015, 2018 updates):

• Ovarian function suppression (OFS) + tamoxifen or exemestane vs. tamoxifen alone
• N = 3,066 premenopausal women with HR-positive early breast cancer
• OFS (goserelin) added benefit in higher-risk patients
• 8-year disease-free survival improved with OFS + endocrine therapy
• Established goserelin as standard OFS agent in breast cancer

TEXT Trial (2018):

• OFS (goserelin) + exemestane vs. OFS + tamoxifen
• N = 2,672 premenopausal women
• OFS with aromatase inhibitor superior to OFS + tamoxifen
• 9-year disease-free survival: 86.8% vs. 82.8%

ZIPP Study (2007):

• 4 randomized trials combined (n=2,710)
• Goserelin vs. CMF chemotherapy in premenopausal breast cancer
• Equivalent efficacy in ER-positive disease
• Goserelin better tolerated with preserved fertility potential

Endometriosis Evidence:

Comparative Studies:

• Goserelin equivalent to danazol for symptom relief
• Significant reduction in endometriotic lesion size
• Bone density loss limits treatment to 6 months
• Add-back therapy preserves efficacy while reducing side effects

Meta-Analyses:

• Cochrane reviews confirm goserelin efficacy equivalent to other GnRH agonists
• No significant efficacy differences between goserelin and leuprolide
• Delivery system differences may affect patient preference

13. Comparison with Alternatives

GnRH Agonists (Same Class):

Key Differentiators for Goserelin:

1. Room temperature storage: Only GnRH agonist not requiring refrigeration
2. Breast cancer indication: Only one FDA-approved for this use
3. Subcutaneous implant: Different technique than IM injections
4. No generic: Higher cost but consistent product

GnRH Antagonists (Degarelix, Relugolix):

Clinical Decision Factors:

Choose Goserelin When:

• Breast cancer indication needed (only FDA-approved GnRH agonist)
• Room temperature storage preferred (logistics, home storage)
• Monthly or quarterly subcutaneous administration acceptable
• Patient established on goserelin with good tolerance

Choose Leuprolide When:

• Generic needed (cost consideration)
• 4 or 6-month formulation desired
• Intramuscular injection preferred
• Pediatric indication (central precocious puberty)

Choose GnRH Antagonist When:

• Rapid castration needed (symptomatic metastases)
• Flare risk unacceptable (spinal cord compression risk)
• Cardiovascular disease concerns
• Patient preference for oral therapy (relugolix)

Surgical Castration (Orchiectomy):

• Permanent, immediate, no ongoing medication
• Lower lifetime cost
• Psychological impact may be significant
• No flare phenomenon
• No compliance concerns

14. Storage and Handling

Storage Requirements:

• Store at controlled room temperature: 15-25°C (59-77°F)
• KEY ADVANTAGE: Does NOT require refrigeration (unique among GnRH agonists)
• Protect from light (store in original carton until use)
• Do not freeze
• Shelf life: 3 years from manufacture date when stored properly

Pre-Administration Preparation:

• Remove from foil pouch immediately before use
• Inspect for damage to syringe or implant
• Check expiration date on packaging
• Do not use if implant is damaged, discolored, or past expiration
• Bring to room temperature if stored in cooler environment

Administration Site Preparation:

• Clean anterior abdominal wall with antiseptic
• Area should be below navel line
• Avoid areas with scars, skin abnormalities, or previous injection sites
• Local anesthetic (1% lidocaine) optional but rarely needed

Implant Insertion Technique:

1. Position patient supine
2. Grasp skin to create fold at injection site
3. Insert needle at 30-45° angle with bevel up
4. Advance needle fully until hub reaches skin surface
5. Depress plunger slowly and completely
6. Withdraw needle along insertion path
7. Apply pressure to site; bandage optional

Post-Administration:

• Implant biodegrades completely; no removal necessary
• Patient may feel small nodule at site initially (normal)
• Mild injection site reactions (pain, redness) may occur
• Significant swelling, persistent pain, or infection signs require evaluation

Disposal:

• Single-use device; discard entire syringe after use
• Dispose of in appropriate sharps container
• Follow local regulations for pharmaceutical waste
• No special hazardous material handling required

Handling Precautions:

• Healthcare provider should wear gloves during administration
• Avoid accidental needle stick (pre-filled syringe)
• Avoid contact with skin if implant is damaged and drug exposed
• Wash immediately if skin contact occurs
• Pregnancy: Women who are or may become pregnant should not handle damaged product

15. References

1. AstraZeneca. Zoladex (goserelin acetate implant) Prescribing Information. Wilmington, DE; 2024.

2. FDA Drug Approval Package: Zoladex (goserelin acetate). NDA 019726. 1989.

3. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol. 1991;67(5):502-508.

4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103-106.

5. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-137.

6. Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34(19):2221-2231.

7. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2024. National Comprehensive Cancer Network.

8. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2024. National Comprehensive Cancer Network.

9. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475-487.

10. FDA Drug Safety Communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. October 2010.

11. Rice MS, Tworoger SS, Bertrand KA, et al. Risk of breast cancer among women treated with gonadotropin-releasing hormone agonists for infertility. Obstet Gynecol. 2019;134(4):770-777.

12. Garnick MB, Mottet N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. 2012;110(4):499-504.

13. Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187-2196.

14. Labrie F. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. Endocr Relat Cancer. 2014;21(4):R301-R317.

15. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391-405.

Paper completed: December 2024 Research paper for educational and clinical reference purposes

Status: PAPER 60 OF 76 COMPLETE

Next Paper: #61 - Triptorelin